

Freedom of Information Request	FOI 21-362	20 th September 2021
--------------------------------	------------	---------------------------------

I am writing to you today to request information relating to the treatment of schizophrenia by your trust

Q1. In the past 6 months, how many patients has your trust treated [for any condition] with the following drugs:

The Health Board is unable to provide the number of patients treated across the Health Board with the specified drugs. However, we have supplied the quantities dispensed for the period March 2021 and August 2021, on the attached spreadsheet.

- **Aripiprazole long-acting injectable (Abilify Maintena)**
- **Olanzapine pamoate (Zypadhera)**
- **Paliperidone palmitate, once monthly (Xeplion)**
- **Paliperidone palmitate, three monthly (Trevicta)**
- **Risperidone long-acting injectable (Risperdal Consta)**
- **Flupentixol decanoate (Depixol)**
- **Fluphenazine decanoate (Modecate)**
- **Haloperidol decanoate (Haldol Decanoate)**
- **Pipotiazine palmitate (Piportil)**
- **Zuclopenthixol decanoate (Clopixol)**

Q2. Within your organisation how many patients are currently [within the past 6 months] being treated for Schizophrenia (ICD code: F20)

The Health Board is only able to provide information in relation to patients that have been admitted into our inpatient units in the last six months with the F20 diagnosis.

Inpatients Admitted	Paranoid schizophrenia	Hebephrenic schizophrenia	Catatonic schizophrenia	Undifferentiated schizophrenia	Post-schizophrenic depression	Residual schizophrenia	Simple schizophrenia	Other schizophrenia	Schizophrenia, unspecified
Month Year	F200	F201	F202	F203	F204	F205	F206	F208	F209
Jan-21	30							1	
Feb-21	13								3
Mar-21	24								2
Apr-21	14	1							3
May-21	23								1
Jun-21	21								2
Jul-21	9								1
TOTALS	134	1	0	0	0	0	0	1	12

Q3. Of the Schizophrenia patients ONLY, how many are currently [within the past 6 months] being treated with the following drugs:

- **Aripiprazole long-acting injectable (Abilify Maintena)**
- **Olanzapine pamoate (Zypadhera)**
- **Paliperidone palmitate, once monthly (Xeplion)**
- **Paliperidone palmitate, three monthly (Trevicta)**

- **Risperidone long-acting injectable (Risperdal Consta)**
- **Flupentixol decanoate (Depixol)**
- **Fluphenazine decanoate (Modecate)**
- **Haloperidol decanoate (Haldol Decanoate)**
- **Pipotiazine palmitate (Piportil)**
- **Zuclopenthixol decanoate (Clopixol)**

The Health Board does not record this information centrally. In order to determine this, the Health Board would have to review every patient record. Therefore in order to comply with your request the Health Board has established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000 which is currently £450. As you will be aware this is not an exemption which requires us to consider the application of the public interest test. We have calculated that it would take in excess of 18 hours to review the record of each patient.